Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
Open Access
- 30 June 2014
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 167 (4) , 563-565
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myelomaLeukemia, 2013
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood, 2012
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood, 2012
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaBritish Journal of Haematology, 2011
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myelomaBlood, 2010
- The role of complete response in multiple myelomaBlood, 2009
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialLeukemia, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus StatementMayo Clinic Proceedings, 2007